Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 10, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 28,843 | $5.13 | 192,047 | |
| Jul 10, 2020 | Chief Medical Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 28,843 | $15.65 | 163,204 | |
| Jul 10, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 28,843 | -- | 11,778 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 29,148 | $6.10 | 556,603 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 29,148 | -- | 6,270 | |
| Mar 01, 2024 | Director, Executive Chairman | Open market or private sale of non-derivative or derivative security | Form 4 | 29,181 | $13.35 | 573,478 | |
| Jan 15, 2021 | Director, Chief Operating Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 29,367 | -- | 393,320 | |
| Jul 25, 2007 | Ten Percent Owner | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 29,447 | $11.49 | 851,183 | |
| Jul 25, 2007 | Ten Percent Owner | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 29,447 | $11.49 | 851,183 | |
| Jul 25, 2007 | Ten Percent Owner | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 29,447 | $11.49 | 851,183 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.